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Abstract 
Background: Patients with treatment-resistant depression (TRD) suffer very significant 
morbidity and are at a disadvantage concerning optimal clinical management. There are 
high associated societal costs.  
Aims: A detailed analysis of health economic costs in the United Kingdom in a group 
manifesting a severe form of TRD in the 12 months before their participation in a major 
randomized controlled treatment trial.  
Methods: The sample consisted of 118 participants from the Tavistock Adult 
Depression Study. Recruitment was from primary care on the basis of current major 
depression disorder of at least 2 years’ duration and two failed treatment attempts. 
Service utilization was assessed based on self-report and general practitioner (GP) 
medical records. Generalized linear models were used to identify predictors of cost. 
Results: All participants used GP services. Use of other doctors and practice nurses was 
also high. The mean total societal cost was £22,124, 80% of which was due to lost work 
and care required of families. Level of general functioning was found to be the most 
consistent predictor of costs. 
Conclusions: Severe forms of TRD are associated with high costs in which unpaid care 
and lost work predominate. Treatments that improve functioning may reduce the large 
degree of burden. 
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Introduction 
Currently, depression is estimated to affect approximately 121 million people 
worldwide and is associated with approximately 850,000 deaths by suicide every year. 
It is the leading cause of disability and is expected to be the second leading contributor 
to the global disease burden by 2020 (Demyttenaere et al., 2004; WHO, 2010). Key 
costs of depression include treatment costs and the costs associated with family care and 
lost employment. The economic burden of major depressive disorder (MDD) was 
estimated at $124 billion in the USA in 2012 (Mrazek et al., 2014) and €118 billion in 
Europe in 2004 (Richards, 2011). In England, in 2007, the total cost of services for 
depression was estimated to be in the region of £1.7 billion; adding lost employment 
increased this by a further £5.8 billion (McCrone et al., 2008). Between 10% and 20% 
of patients with a major depressive episode (Kessler et al., 2003; Kubitz et al., 2013) 
will go on to suffer more complex and protracted forms of depression, with poor 
responses to treatment and major effects on work functioning, interpersonal 
relationships, and quality of life (Greden, 2001). These forms are frequently termed 
treatment-refractory or treatment-resistant depression (TRD). However, while there 
appears to be a general consensus on the definition of chronic depression (a minimum 
of a 2-year period), there are inconsistencies surrounding the definition of TRD (Berlim 
& Turecki, 2007). These inconsistencies make it difficult to discern its actual 
prevalence. High rates of non-response of depressed patients to treatments in general 
have been reported (Simon et al., 2002; Thomas et al., 2013), with 12–20% of depressed 
patients not benefiting even from multiple courses of treatment (Kubitz et al., 2013). 
These patients have also been found to make a disproportionate contribution to the 
economic burden associated with the spectrum of depressive disorders (Crown et al., 
2002; Ivanova et al., 2010). For example, studies suggest that compared with patients 
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suffering from chronic depression, patients with TRD have significantly higher costs for 
imaging tests, physician visits and psychiatric hospitalization (Fostick et al., 2010), as 
well as for direct medical expenditures (Olchanski et al., 2013).  
The aim of this study is to investigate the costs associated with this patient group in the 
United Kingdom (UK). The sample consisted of participants from the Tavistock Adult 
Depression Study (TADS; Fonagy et al., 2015), who were referred from primary care 
with a diagnosis of MDD of at least 2 years’ duration and at least two failed treatment 
attempts. Specifically, we aimed: (i) to measure service use and lost employment and 
their associated costs over the 1-year period before randomization into the study; and 
(ii) to identify any particular clinical and demographic characteristics associated with 
these costs. 
Method 
Data and study design 
This study was a retrospective analysis of service use and costs of the participants 
recruited to the TADS. The TADS was a pragmatic randomized controlled trial set up to 
investigate the effectiveness of long-term psychoanalytic psychotherapy (LTPP) 
compared with treatment as usual (TAU) delivered according to UK national guidelines 
as arranged by the participants’ primary care providers. Detailed descriptions of the 
study design and outcome findings are available elsewhere (Fonagy et al., 2015; Taylor 
et al., 2012). In brief, participants were recruited from GP practices from central and 
north London from February 2002 to May 2009. Patients were eligible if they were aged 
over 18; had a current diagnosis of MDD as assessed by the Structured Clinical 
Interview for DSM-IV (SCID-I; First et al., 2001); reported a minimum duration of 2 
years of the current depressive episode; scored a minimum of 14 on the 17-item version 
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of the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1967) and 21 on the 
Beck Depression Inventory (BDI-II; Beck et al., 1996); and had at least two failed 
treatment attempts, one of which must have included an antidepressant medication 
(ADM), while the other could include either an ADM from a different class or a 
psychological therapy. Patients with a diagnosis of psychotic disorder, bipolar disorder, 
psychiatric input for substance abuse or dependency, mild or severe learning disability, 
and evidence of organic brain disorder were excluded. Ethical approval was sought and 
approved by the Institutional Review Board of the NHS West Midlands Research Ethics 
Committee (MREC02/07/035). 
Service use and cost 
Participants recruited into the trial (n=129) completed an adapted version of the Client 
Service Receipt Inventory (CSRI; Beecham & Knapp, 2001) as part of a comprehensive 
assessment, and consented to the study accessing their GP medical records. The 
information in the CSRI was provided by the participants and covered the 12-month 
period before randomization into the trial. Information collected included: number and 
duration of contacts with primary and secondary health and social care services; unpaid 
informal care received, such as help with child care, personal care, help in and around 
the home, and help outside the home; employment status; and days of lost employment. 
The same information was also extracted from the participant’s medical records by two 
independent researchers. To achieve reliability of data extraction, a third researcher 
clarified any discrepancies and an average was calculated in cases of a confirmed major 
difference. For the current analysis, both data sources were combined. A societal 
perspective was adopted in which both costs to the health and social care system and the 
broader impacts on productivity and families were included. Service use data were 
combined with nationally representative information on unit costs. For most services 
these unit costs were drawn from an annually updated source (Curtis, 2010). Hospital 
costs were obtained from routine data collected by the UK Department of Health 
(Department of Health, 2011). For the cost of informal care we used an average hourly 
wage rate of £14.60; lost employment costs were calculated using an average daily 
wage rate of £97.52 (Office for National Statistics, 2011). 
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Data analysis 
Analyses were conducted on all cases providing service use data. These were baseline 
data and so no imputation for missing cases was conducted. However, where quantities 
of specific service use was missing we used median values for others using that 
services.  Descriptive statistics were produced for socio-demographic characteristics; 
length and severity of depression; functioning, as measured with the Global Assessment 
of Functioning Scale (GAF; Hilsenroth et al., 2000); and Generalized Anxiety Disorder 
(GAD), as measured with the SCID-I (First et al., 2001), coded here as a binary variable 
comparing moderate or severe versus mild or no levels. The number and percentage of 
participants using specific services is reported and the mean number and standard 
deviation (SD) of contacts by those who used them, as well as the mean and SD cost for 
the whole sample (i.e. including those not using specific services). Univariate 
descriptive analyses were conducted to observe the relationship between demographic 
and clinical characteristics and cost categories (healthcare, informal care plus lost 
employment, and total cost). This was followed by regression analyses using the same 
variables and cost categories, using Stata version 11. As costs tend to follow a skewed 
distribution, we used generalized linear models with a gamma family and log link 
function (Mihaylova et al., 2011) in order to identify cost predictors. This was due to 
the positively skewed cost distribution. In these exploratory analyses statistical 
significance was assumed at the P<0.1 level.  
Results 
Characteristics of the sample 
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Of the 129 participants randomized into the study, health economic data were available 
for 118 (91.5%). Table 1 provides a summary of their socio-demographic and 
diagnostic characteristics. As per protocol, all patients had a diagnosis of current MDD; 
76% had an additional diagnosis of early-onset dysthymia and 37% had a comorbid 
diagnosis of GAD (13% mild and 25% moderate/severe levels). The average total 
duration of depression was 25.4 years (SD=12.42) and the average length of the current 
depressive episode was 3.7 years (SD=3.01). In terms of depression severity, 75% 
scored within the severe range on the BDI-II (mean=36.2, SD=9.8) and 64% within the 
severe-very severe range on the HRSD-17 (mean=21.4, SD=5.6). The mean GAF score 
was 48.7 (SD=7.6) indicating serious functional impairment. The characteristics of the 
118 participants for whom we obtained cost data were very similar to those of the 129 
participants comprising the full sample (details available from the authors).  
Table 1 
Sample characteristics 
Characteristic n % 
Gender 
 Male 
 Female 
 
40 
78 
 
34 
66 
Age 
 19–30 
 31–40 
 41–50 
 51–60 
 61–70 
 
15 
27 
37 
31 
8 
 
13 
23 
31 
26 
7 
Marital status 
 Single/widowed/divorced 
 Married/cohabiting 
 
100 
18 
 
84 
15 
Ethnicity 
 White 
 Other 
 
97 
21 
 
82 
18 
Employment status 
 Employed full-time 
 Employed part-time 
 Unemployed 
 Self-employed 
 Retired 
 
25 
16 
64 
7 
6 
 
21 
13 
54 
6 
5 
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Severity at baseline (BDI-II) 
 21–39  
 40+ 
 
75 
43 
 
64 
36 
BDI-II severity   
 Mild (14–19) 5 4 
 Moderate (20–28) 25 21 
 Severe (29–63) 88 75 
HRSD-17 severity   
 Mild (8–13) 11 9 
 Moderate (14–18) 32 27 
 Severe (19–22) 20 17 
 Very severe (23+) 55 47 
GAF   
 <40 (severe impairment) 16 13 
 41–50 (serious impairment) 48 41 
 51+ (moderate impairment) 54 46 
GAD   
 None/mild 89 75 
 Moderate/severe 29 25 
 
 
Service use and costs 
Table 2 shows the number of the sample using specific services and, for those who had 
use, how many times on average this occurred. Costs are also shown for the whole 
sample. Only a small number of participants had been psychiatric inpatients in the 12 
months before joining the trial; however, one in six had had hospital admissions for 
physical health problems. All patients reported having had GP contacts: their average 
frequency was slightly less than one per month. More than two-thirds of the sample had 
practice nurse contacts; a similar number had outpatient contacts for physical health 
problems. Nearly half the sample reported receiving informal care from family/friends 
in the previous 12 months due to their health problems. Two-thirds of participants had 
had lost employment due to health problems (either days off sick or out of work). 
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Table 2 
Use and costs of services in 12 months prior to interview (in 2009/10, £) 
Service Number  
using 
service 
% 
using 
service 
Mean 
contacts  
by users 
SD of 
contacts 
Mean 
cost 
for 
whole 
sample 
SD of 
cost 
Psychiatric inpatient 4 3 15.3 10.4 188 1131 
Physical inpatient 20 17 9.7 17.8 816 3426 
Psychiatric outpatient 11 9 16.3 19.0 175 872 
Physical outpatient 84 71 9.2 22.1 855 2804 
Psychiatric day hospital 3 3 145.3 22.0 358 2255 
Physical day hospital 7 6 1.9 1.2 177 1321 
Accident and 
emergency 
34 29 1.7 1.1 57 111 
GP 119 100 10.8 6.2 511 405 
Practice nurse 82 69 3.2 3.6 18 30 
District nurse 2 2 10.5 13.4 3 26 
Community mental 
health treatment 
14 12 6.2 13.5 23 142 
Other nurse 2 2 10.5 13.4 4 35 
Health visitor 1 1 1.0 - 1 6 
Counsellor 51 43 8.8 12.7 149 369 
Psychologist 28 24 9.4 15.7 174 684 
Psychiatrist 22 18 4.7 4.5 201 613 
Occupational Therapist 11 9 1.7 1.2 5 18 
Social worker 9 8 3.3 4.2 22 114 
Homecare worker 4 3 58.5 13.0 284 1901 
Community support 
worker 
6 5 16.7 18.8 23 143 
Housing worker 7 6 3.9 3.0 9 66 
Voluntary worker 4 3 29.8 23.5 23 150 
Day centre 3 3 35.2 25.4 14 111 
Self-help group 8 7 33.0 50.4 27 180 
Other therapist 24 20 9.0 13.9 110 436 
Alternative therapy 17 14 22.3 62.4 59 396 
Community doctor 4 3 12.5 13.2 28 216 
Physiotherapist 8 7 7.1 6.2 22 107 
Dietitian 1 1 2.0 - 1 13 
Antidepressants 99 83 - - 51 125 
Total service costs - - - - 4388 7347 
       
Informal care 57 48 16 28 5772 16053 
Lost employment for 
participants 
80 67   11964 12678 
Total indirect costs     17736 20605 
       
Total cost     22124 23466 
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The services with the highest mean costs were inpatient care, outpatient visits, day 
hospital attendances and GP contacts. Together, they accounted for 70% of the total 
average healthcare cost of £4388 (SD=£7347). However, informal care from 
family/friends was responsible for a higher proportion of the costs than those of health 
and social care services, and lost employment in particular was responsible for over 
twice the amount for health and social care. These social and employment categories 
accounted for 26% and 54%, respectively, of the total mean cost of £22,124 (SD = 
£23,466). 
Health and social care services costs were somewhat higher for women than for men; 
this gender difference held for informal care and lost employment costs as well (see 
Table 3). Participants in the 41–50 and 51–60 age groups had the highest health and 
social care costs. Costs were also higher for married/cohabiting participants and those of 
non-white ethnicity. Costs associated with informal care and lost employment were 
highest for those aged 31–40. Overall costs were highest for participants who were 
unemployed. Participants with higher baseline depression severity had higher costs than 
those whose depression was less severe. Better functioning, as measured with the GAF, 
was associated with lower formal health and social care costs; the association between 
GAF and the costs of informal care and lost employment was less clear. 
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Table 3 
Univariate analysis of costs (in 2009/10, £) 
Characteristic Health and 
social care 
cost 
Informal care 
and lost 
employment 
cost 
Total cost 
Gender 
 Male 
 Female 
 
3271 
4953 
 
16409 
18409 
 
19680 
23362 
Age 
 21–30 
 31–40 
 41–50 
 51–60 
 61–70 
 
2283 
2377 
6383 
5062 
3200 
 
7385 
26324 
18319 
17672 
5724 
 
9668 
28701 
24702 
22734 
8924 
Marital status 
 Single/widowed/divorced 
 Married/cohabiting 
 
3871 
7111 
 
16925 
22008 
 
20795 
29120 
Ethnicity 
 White 
 Other 
 
3969 
6345 
 
16278 
24545 
 
20246 
30889 
Employment status 
 Employed full-time 
 Employed part-time 
 Unemployed 
 Self-employed 
 Retired 
 
3464 
2375 
5696 
1340 
2992 
 
4366 
2505 
29816 
1924 
1645 
 
7830 
4881 
35512 
3264 
4637 
Severity at baseline (BDI-II) 
 21–39 
 40+ 
 
3186 
6879 
 
11524 
27803 
 
14710 
34682 
GAD 
 None/mild 
 Moderate/severe 
 
4008 
5566 
 
18440 
15553 
 
22448 
21119 
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GAF total 
 <40 (severe impairment) 
 41–50 (serious impairment) 
 51+ (moderate impairment) 
 
8449 
5798 
3502 
 
15452 
33028 
11600 
 
23901 
38826 
15102 
 
 
Table 4 shows the results of the regression analysis of costs against the independent 
variables of gender, age, relationship status, ethnicity, depression severity, and 
functioning (GAF). After controlling for other characteristics, participants aged 51–60 
were shown to have health and social care costs that were on average 140% higher than 
those aged 19–30. Higher GAF scores (i.e. indicating better function) were associated 
with lower health and social care costs: a one-unit increase in the GAF was associated 
with a 3% reduction in costs. The costs associated with informal care and lost 
employment of participants aged 31–40 were significantly higher than those aged 19–
30. Married/cohabiting participants had higher costs than those who were single, 
widowed, or divorced. If baseline depression severity scored 40 or above on the BDI-II 
then informal care and lost employment costs were significantly increased. Again, the 
GAF score was inversely related to cost. Total costs were positively related to those 
aged 31–40, 41–50 and 51–60, participants who were married/cohabiting and those 
from a non-white ethnic group.  
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Table 4 
Multivariate analysis of cost (in 2009/10, £) 
Characteristic Health and social 
care cost 
Informal care and 
lost employment cost 
Total cost 
 Exp 
coeff2 
P Exp coeff P Exp 
coeff 
P 
Female 1.452 0.162 0.780 0.352 0.932 0.550 
Age1 
 31–40 
 41–50 
 51–60 
 61–70 
 
1.110 
1.933 
2.398 
1.420 
 
0.804 
0.105 
0.027 
0.551 
 
3.026 
2.069 
1.739 
0.769 
 
0.001 
0.056 
0.185 
0.395 
 
2.632 
2.251 
2.071 
1.037 
 
<0.001 
0.014 
0.028 
0.648 
Married/cohabiting 1.496 0.317 1.799 0.014 1.643 0.010 
White ethnicity 0.679 0.247 0.671 0.259 0.609 0.050 
Severity 40+ (BDI-
II) 
1.518 0.161 1.490 0.046 1.489 0.052 
Moderate/severe 
GAD 
1.160 0.606 0.629 0.204 0.755 0.454 
GAF total score 0.968 0.038 0.943 0.001 0.952 <0.001 
1 Reference category 21–30  
2Exp coeff = exponentiated coefficient. It indicates the proportional change (where 1 
represents no change) in costs associated with a one-unit change in the independent 
variables.   
 
 
Discussion 
This study measured the service use and costs over a 1-year period for patients with 
severe and complex forms of depression, commonly referred to as TRD. We found that 
the mean annual cost for individuals in this patient group in 2009/10 prices was high, at 
£22,124. This is comparable to the costs associated with dementia and schizophrenia 
(McCrone et al., 2008). In current (2015/16) prices the figure would be approximately 
£25,000. Our figures are at least seven times as high as those reported by another recent 
UK study evaluating costs in a sample of patients suffering from TRD using a societal 
perspective (Hollinghurst et al., 2014). However, differences in the definition of TRD 
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indicate that the sample in that study was less severely affected than ours. This 
difference emphasizes the need for precision in terms of defining the characteristics of 
these patients and the importance of establishing a commonly accepted definition of 
TRD. 
The prevalence of depressive episodes in the general adult population of England has 
been reported to be 2.3% (McManus et al., 2009), indicating that in 2016 the total 
number of individuals with depression in England was estimated to be 1.3 million 
(McCrone et al., 2008). Epidemiological studies in the UK, like those of other countries 
(see Bromet et al., 2011), reveal that in many patients depression does not remit 
completely. Studies of the natural course of depression generally find that half of 
patients will still meet diagnostic criteria after a year (Simon et al., 2002). This 
corresponds to the sample whose costs were evaluated in the study of Hollinghurst et al. 
(2014). However, on the basis that 12% of depressed patients (Andrade et al., 2003) fall 
into a category resembling that corresponding to the definition of TRD employed in our 
study, the costs in the UK of this part of the depressive spectrum can be estimated to be 
in the region of £3.9 billion. In the present study, lost employment and informal care 
costs were found to account for 54% of the total, and formal service and treatment costs 
for only 26%. The dominance of lost employment costs agrees with the findings of 
previous studies (e.g. Broadhead et al., 1999; Curran et al., 2007; Kessler & Frank, 
1997). The most expensive formal service costs were those for physical inpatient and 
outpatient care, and GP contacts. Notably, in spite of the evident severity of the 
condition suffered by this patient group, surprisingly few were admitted to hospital for 
psychiatric care.  
In exploring the variations in costs between individuals, we found that level of 
functioning was significantly and inversely related to health/social care costs and also to 
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informal care/lost employment costs. The strength of this relationship may have reduced 
the figure for the impact of depression symptom severity on costs; the latter was 
statistically significant only for informal care/lost employment. Given that these latter 
costs account for the larger fraction of the total costs, points to the important possibility 
that treatments whose mode of action aims to directly reduce the level of functional 
impairment (or, conversely, increase functional capacity) may more effectively reduce 
the economic burden of TRD than those thought to act on symptoms more narrowly. 
Andrews (2001) concluded that the burden of disease attributable to depressive 
disorders has not fallen in higher-income countries even though evidence-based 
treatments deemed to address mental state symptoms have become more widely 
available. Likely this will apply to TRD patients. Finally, it might seem counter-
intuitive that total costs were found to be higher for those who were married/cohabiting. 
Most likely this reflects the greater availability of informal care for these participants 
rather than indicating the existence of an intrinsic difference between 
married/cohabiting patients and those living alone. 
Limitations 
Unfortunately, while the GAF is widely used as a proxy of both functioning and 
symptoms, it has severe limitations as a measure of the many domains involved in 
functional capacity/impairment (Dimsdale et al., 2010; Smith et al., 2011). In addition 
to the GAF, we used participant self-report of service use data supplemented by 
information from medical records. Both sources may not be fully accurate. Recall 
accuracy can be a problem for self-report data, although studies have shown it to be a 
reasonable approach (Calsyn et al., 1993; Goldberg et al., 2002). Administrative records 
may be more accurate for some services (e.g. GP contacts, days in hospital), but may 
not capture as broad a range of data as self-reporting.  
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A second limitation is that the study was carried out in a particular area of London, 
albeit one with diverse populations and spanning many socioeconomic conditions, and 
that the sample consisted of those referred for specialist care. Generalizing the findings 
to other settings and healthcare systems needs thus to be done cautiously. Given its high 
costs, this is especially pertinent to inpatient care.  
Third, the costs reported included all services used by patients with TRD and not 
necessarily those used specifically because of TRD. As shown, one in six of the 
participants accessed services in connection with physical health problems. The 
existence of complex interactions between depression, physical symptoms, and physical 
illness is well known. Individuals diagnosed with depression have been found to have 
higher comorbidity with physical problems and vice versa (e.g. Choi et al., 2014; Smith 
et al., 2011; Stegmann et al., 2010). A matched comparison of groups of non-depressed 
and depressed non-TRD participants, controlling for physical health/illness, would be 
required to tease apart the impact of physical and mental health problems. 
Conclusion 
Despite these limitations, the findings of the present study highlight that severe forms of 
TRD are associated with high costs, in which unpaid care and lost work predominate. 
Our findings support the idea that research on treatments that might act on the 
mechanisms that may exist between impaired levels of functioning and vulnerability to 
ongoing depression would be particularly valuable.  
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